Total Payments
$5,243
2024 Payments
$15.50
Companies
39
Transactions
263
Medicare Patients
8,204
Medicare Billing
$491,461
Payment Breakdown by Category
Food & Beverage$3,073 (58.6%)
Research$2,066 (39.4%)
Education$104.99 (2.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,073 | 251 | 58.6% |
| Unspecified | $2,066 | 10 | 39.4% |
| Education | $104.99 | 2 | 2.0% |
Payments by Type
General
$3,178
253 transactions
Research
$2,066
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI US SERVICES INC. | $1,072 | 7 | $0 (2018) |
| Eli Lilly and Company | $993.94 | 3 | $0 (2023) |
| Allergan, Inc. | $516.93 | 69 | $0 (2020) |
| GlaxoSmithKline, LLC. | $310.15 | 23 | $0 (2024) |
| PFIZER INC. | $254.63 | 18 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $198.43 | 10 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $198.08 | 17 | $0 (2020) |
| Astellas Pharma US Inc | $161.34 | 7 | $0 (2020) |
| Sunovion Pharmaceuticals Inc. | $160.99 | 11 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $134.71 | 10 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15.50 | 1 | GlaxoSmithKline, LLC. ($15.50) |
| 2023 | $372.10 | 5 | Eli Lilly and Company ($297.96) |
| 2022 | $447.00 | 1 | Eli Lilly and Company ($447.00) |
| 2021 | $248.98 | 1 | Eli Lilly and Company ($248.98) |
| 2020 | $661.24 | 51 | Allergan, Inc. ($156.72) |
| 2019 | $642.08 | 48 | Sunovion Pharmaceuticals Inc. ($139.17) |
| 2018 | $1,604 | 63 | SANOFI US SERVICES INC. ($1,072) |
| 2017 | $1,252 | 93 | Allergan Inc. ($200.71) |
All Payment Transactions
263 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/25/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: VACCINES | ||||||
| 09/22/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: VACCINES | ||||||
| 06/06/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $15.72 | General |
| Category: RESPIRATORY | ||||||
| 04/19/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: VACCINES | ||||||
| 02/09/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $20.81 | General |
| Category: VACCINES | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $297.96 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $447.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | ||||||
| 03/17/2021 | Eli Lilly and Company | — | — | In-kind items and services | $248.98 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | ||||||
| 12/18/2020 | Allergan, Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.12 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2020 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: Cardiovascular | ||||||
| 12/15/2020 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: GASTROINTESTINAL | ||||||
| 12/11/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $12.96 | General |
| Category: NEUROSCIENCE | ||||||
| 11/28/2020 | Allergan, Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2020 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: GASTROINTESTINAL | ||||||
| 11/16/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO RESPIMAT (Drug), SPIRIVA RESPIMAT | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: RESPIRATORY | ||||||
| 11/10/2020 | Allergan, Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.23 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2020 | Allergan, Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.18 | General |
| Category: NEUROSCIENCE | ||||||
| 10/28/2020 | AstraZeneca Pharmaceuticals LP | BREZTRI AEROSPHERE (Drug) | Food and Beverage | In-kind items and services | $11.95 | General |
| Category: Respiratory | ||||||
| 10/27/2020 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: Neuroscience | ||||||
| 10/22/2020 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $11.74 | General |
| Category: Neuroscience | ||||||
| 10/19/2020 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: GASTROINTESTINAL | ||||||
| 10/10/2020 | Ultragenyx Pharmaceutical Inc. | — | Food and Beverage | In-kind items and services | $21.06 | General |
| 10/08/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO RESPIMAT (Drug), SPIRIVA RESPIMAT | Food and Beverage | In-kind items and services | $11.75 | General |
| Category: RESPIRATORY | ||||||
| 10/07/2020 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $11.74 | General |
| Category: Neuroscience | ||||||
| 10/01/2020 | PFIZER INC. | CHANTIX (Drug), EUCRISA, COLOGUARD | Food and Beverage | In-kind items and services | $11.69 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular | SANOFI US SERVICES INC. | $1,072 | 7 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $695.98 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $297.96 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 1,882 | 3,014 | $255,403 | $119,193 |
| 2022 | 29 | 2,033 | 3,203 | $247,277 | $114,422 |
| 2021 | 31 | 2,217 | 3,468 | $272,645 | $136,687 |
| 2020 | 33 | 2,072 | 3,263 | $246,932 | $121,159 |
Total Patients
8,204
Total Services
12,948
Medicare Billing
$491,461
Procedure Codes
119
All Medicare Procedures & Services
119 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 261 | 551 | $84,394 | $44,576 | 52.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 131 | 368 | $26,436 | $13,489 | 51.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 106 | 207 | $21,543 | $12,171 | 56.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 83 | 93 | $18,222 | $8,814 | 48.4% |
| 94375 | Test to measure rate of airflow | Office | 2023 | 128 | 203 | $15,428 | $5,275 | 34.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 49 | 58 | $9,336 | $4,939 | 52.9% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 20 | 23 | $12,098 | $4,710 | 38.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 59 | 68 | $6,843 | $3,427 | 50.1% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 140 | 201 | $6,030 | $3,143 | 52.1% |
| 94664 | Evaluation of use of breathing device | Office | 2023 | 152 | 250 | $10,500 | $2,877 | 27.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 194 | 255 | $4,272 | $2,138 | 50.0% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2023 | 57 | 57 | $3,876 | $1,909 | 49.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 59 | 59 | $2,950 | $1,689 | 57.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 14 | 14 | $2,450 | $1,682 | 68.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 81 | 160 | $5,280 | $1,547 | 29.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 54 | 54 | $7,182 | $1,457 | 20.3% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 45 | 51 | $2,499 | $1,225 | 49.0% |
| 94667 | Initial therapy service to facilitate lung function | Office | 2023 | 57 | 58 | $3,190 | $935.76 | 29.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 15 | 16 | $1,792 | $935.73 | 52.2% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 52 | 74 | $5,920 | $650.67 | 11.0% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 30 | 46 | $966.00 | $631.58 | 65.4% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 13 | 13 | $1,768 | $502.19 | 28.4% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 27 | 40 | $1,600 | $227.41 | 14.2% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 13 | 13 | $650.00 | $168.30 | 25.9% |
| 81003 | Automated urinalysis test | Office | 2023 | 22 | 24 | $120.00 | $52.80 | 44.0% |
About Dr. Brian Heimer, MD
Dr. Brian Heimer, MD is a Family Medicine healthcare provider based in New Albany, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1972597540.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Heimer, MD has received a total of $5,243 in payments from pharmaceutical and medical device companies, with $15.50 received in 2024. These payments were reported across 263 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($3,073).
As a Medicare-enrolled provider, Heimer has provided services to 8,204 Medicare beneficiaries, totaling 12,948 services with total Medicare billing of $491,461. Data is available for 4 years (2020–2023), covering 119 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location New Albany, IN
- Active Since 09/09/2005
- Last Updated 03/21/2021
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1972597540
Products in Payments
- SAR439977 (Drug) $1,072
- VRAYLAR (Drug) $209.09
- LONHALA MAGNAIR (Drug) $139.35
- XARELTO (Drug) $129.81
- SHINGRIX (Biological) $122.56
- BYSTOLIC (Drug) $100.84
- LYRICA (Drug) $97.85
- Vascepa (Drug) $92.84
- LINZESS (Drug) $90.51
- MOVANTIK (Drug) $84.46
- COLOGUARD (Device) $81.75
- Yupelri (Drug) $78.94
- ANORO (Drug) $77.45
- INVOKANA (Drug) $68.27
- UBRELVY (Drug) $65.88
- TOUJEO (Drug) $64.75
- VIBERZI (Drug) $63.44
- Minimed 670G System (Device) $62.81
- Repatha (Biological) $55.68
- Victoza (Drug) $53.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in New Albany
Dennis Ruppel, Md, MD
Family Medicine — Payments: $36,711
Family Medicine $36,711
Dr. Michael Bittenbender, M.d, M.D
Family Medicine — Payments: $17,879
Family Medicine $17,879
Adriana Spanova, Md, MD
Family Medicine — Payments: $16,262
Family Medicine $16,262
Angela Crone, Md, MD
Family Medicine — Payments: $15,736
Family Medicine $15,736
Ronald Scott, D.o, D.O
Family Medicine — Payments: $14,060
Family Medicine $14,060
Dr. Cassandra Bittenbender, M.d, M.D
Family Medicine — Payments: $13,817
Family Medicine $13,817